Holen Sie sich die Stockscreener-App
1.975
9.40%
-0.205
Handel nachbörslich:
2.01
0.035
+1.77%
Schlusskurs vom Vortag:
$2.18
Offen:
$2.12
24-Stunden-Volumen:
104.88K
Relative Volume:
0.63
Marktkapitalisierung:
$146.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.631
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
-16.67%
1M Leistung:
-13.00%
6M Leistung:
+55.51%
1J Leistung:
-8.14%
1-Tages-Spanne:
$1.92
$2.12
1-Wochen-Bereich:
$1.92
$2.39
52-Wochen-Spanne:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
678-392-3419
Adresse
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.975 | 146.82M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India
HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - GlobeNewswire
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria
Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire
Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks
Inhibikase enhances leadership with new appointments - Investing.com
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN
Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat
Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter
Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn
Inhibikase shelves Parkinson’s asset after Phase 2 flop - Endpoints News
Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing R - GuruFocus.com
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock - Yahoo Finance
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Top 5 Small-cap Pharma Stocks (Updated January 2025) - Investing News Network
Inhibikase Therapeutics Completes Amendment to Certificate of IncorporationAtlanta, Georgia – Inhibikase Therapeutics, Inc. (NYSE:IKT) recently announced the successful completion of a Special Meeting of Stockholders on January 3, 2025. During this m - Defense World
Inhibikase Therapeutics expands authorized shares - Investing.com India
Inhibikase Therapeutics expands authorized shares By Investing.com - Investing.com Australia
Contrasting CRISPR Therapeutics (NASDAQ:CRSP) & Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% HigherTime to Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher – Still a Buy? - Defense World
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Inhibikase Therapeutics Hits 52-Week High, Surpassing Market Expectations with 198% Growth - mediahousepress
Inhibikase stock soars to 52-week high, hits $3.88 - Investing.com
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):